The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
121 / 207
Overall Ranking
308 / 4721
Industry
Healthcare Equipment & Supplies
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
1.430
Target Price
+219.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 37.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 22.47M.
Fairly Valued
The company’s latest PE is -4.61, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 161.77M shares, increasing 15.79% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.18.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.